LBT-3627

LBT-3627 is an experimental peptide drug derived from vasoactive intestinal peptide (VIP) intended to modulate the behavior of immune cells in cases of neurodegenerative disease such that they protect dopamine-producing cells rather than attack them. The drug is currently being studied for its potential use in the treatment of Parkinson's disease.

Function
LBT-3627 specifically targets the VIP2 receptor. The drug may also have an effect on microglia. LBT-3627 has been shown to be more stable in the body as compared to VIP.

History and development
Researchers at the University of Nebraska Medical Center and Longevity Biotech, Inc. in Philadelphia first demonstrated the use of the drug in mouse models.

A phase I trial for humans was planned for 2017, but as of 2018 it was still in the preclinical development stage.